Novartis Tabrecta Is First Treatment For NSCLC With METex14 Mutation

The US FDA granted an accelerated approval for the lung cancer treatment targeting a mutation found in only about 4,000-5,000 NSCLC patients in the US each year.

lung cancer concept. doctor explaining results of lung check up from x-ray scan chest on digital tablet screen to patient.
Novartis' Tabrecta is approved by FDA for a NSCLC mutation • Source: Shutterstock

Novartis AG's Tabrecta (capmatinib) is the first therapy approved by the US Food and Drug Administration (FDA) targeting metastatic non-small cell lung cancer (NSCLC) with a mutation that leads to MET exon 14 skipping (METex14). The drug was approved by the FDA on 6 May along with a FoundationOne companion diagnostic to detect METex14 mutations.

The mutations only affect a small number of patients with NSCLC – about 4,000-5,000 patients a year in the US,...

Welcome to Scrip

Create an account to read this article

More from New Products

More from Scrip